Suppr超能文献

基于分子对接和动态模拟,鉴定秋水仙碱衍生物作为潜在的多因素药物靶点抑制剂,这些靶点与阿尔茨海默病有关。

identification of colchicine derivatives as novel and potential inhibitors based on molecular docking and dynamic simulations targeting multifactorial drug targets involved in Alzheimer's disease.

机构信息

Department of Chemistry, Jamia Millia Islamia, New Delhi, India.

School of Computational and Integrative Sciences, Jawahar Lal Nehru University, New Delhi, India.

出版信息

J Biomol Struct Dyn. 2024;42(21):11555-11573. doi: 10.1080/07391102.2023.2263586. Epub 2023 Oct 11.

Abstract

Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder, characterized by a gradual and steady deterioration in cognitive function over time. At least 50 million people worldwide are considered to have AD or another form of dementia. AD is marked by a gradual decline in cognitive abilities, memory deterioration and neurodegenerative transformations within the brain. The intricate and multifaceted nature of polygenic AD presents significant challenges within the landscape of drug development. The pathophysiology of AD unfolds in a non-linear and dynamic pattern, encompassing various systems and giving rise to a multitude of factors and hypotheses that contribute to the disease's onset. These encompass theories such as the beta-amyloid hypothesis, cholinergic hypothesis, tau hypothesis, oxidative stress and more. In the realm of drug development, polypharmacological drug profiles have emerged as a strategy that can yield combined or synergistic effects, effectively mitigating undesirable side effects and significantly enhancing the therapeutic efficacy of essential medications. With this concept in mind, our study sought to delve into the binding interactions of a diverse array of colchicine derivative compounds. These derivatives are chosen for their potential anti-inflammatory, antioxidant, anti-neurodegenerative and neuroprotective properties against Alzheimer's and other neurodegenerative diseases. We investigated compound interactions with AD-related targets, utilizing comprehensive molecular docking and dynamic simulations. COM111X showed impressive docking with acetylcholinesterase, indicating potential as an anti-Alzheimer's drug. COM112Y displayed strong docking scores with PDE4D and butyrylcholinesterase, suggesting dual inhibition for Alzheimer's treatment. Further and studies are warranted to explore these findings.Communicated by Ramaswamy H. Sarma.

摘要

阿尔茨海默病(AD)是最常见的神经退行性疾病,其特征是随着时间的推移认知功能逐渐而稳定地恶化。全球至少有 5000 万人被认为患有 AD 或其他形式的痴呆症。AD 的特征是认知能力逐渐下降、记忆力恶化和大脑内的神经退行性变化。多基因 AD 的复杂和多方面性质在药物开发领域带来了重大挑战。AD 的病理生理学以非线性和动态模式展开,涉及各种系统,并产生许多因素和假设,这些因素和假设导致疾病的发生。这些理论包括β-淀粉样蛋白假说、胆碱能假说、tau 假说、氧化应激等。在药物开发领域,多药效药物特征已成为一种策略,可以产生联合或协同作用,有效减轻不良副作用,并显著提高基本药物的治疗效果。考虑到这一概念,我们的研究旨在深入研究一系列秋水仙碱衍生物化合物的结合相互作用。这些衍生物因其具有抗炎、抗氧化、抗神经退行性和神经保护作用而被选择用于治疗 AD 和其他神经退行性疾病。我们利用综合分子对接和动态模拟研究了化合物与 AD 相关靶点的相互作用。COM111X 与乙酰胆碱酯酶表现出令人印象深刻的对接,表明其有作为抗 AD 药物的潜力。COM112Y 与 PDE4D 和丁酰胆碱酯酶表现出强烈的对接评分,表明其具有双重抑制作用,可用于治疗 AD。需要进一步和更深入的研究来探索这些发现。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验